Dudediligence.

Spyre Therapeutics, Inc

SYRENASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$0.00Dec ’24
Net income, by quarter
−$69.0MSep ’24−$56.3MDec ’24−$44.8MMar ’25−$36.7MJun ’25−$11.2MSep ’25−$62.5MDec ’25−$69.0MMar ’26−$36.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$18.7M$2.3M$886,000$0.00$0.00
Operating income−$65.6M−$84.8M−$242.3M−$208.6M−$209.6M
Net income−$65.8M−$83.8M−$338.8M−$208.0M−$155.2M
Operating cash flow−$53.7M−$80.1M−$99.9M−$157.4M−$169.3M
Free cash flow−$54.3M−$80.2M−$99.9M−$157.4Mnone on file
Cash$15.1M$34.9M$188.9M$89.4M$85.7M
Shares outstanding49.4M2.6M36.1M60.3M78.2M